Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer.
Authors
Bronchud, MScarffe, J Howard
Thatcher, Nick
Crowther, Derek
Souza, L M
Alton, N K
Testa, Nydia G
Dexter, T Michael
Affiliation
Cancer Research Campaign Department of Medical Oncology, Christie Hospital, Manchester, U.K.Issue Date
1988-08
Metadata
Show full item recordAbstract
Twelve patients with advanced small cell carcinoma of the bronchus were treated by continuous infusion of recombinant human granulocyte colony-stimulating factor (rh G-CSF) at the following dose levels: 1 microgram, 5 micrograms, 10 micrograms, 20 micrograms and 40 micrograms/kg/day for 5 days. No toxicities resulted from the treatment and in all 12 patients the number of peripheral neutrophils increased rapidly to a maximum of 100 x 10(9)/l in one patient at 10 micrograms/kg/day. The neutrophils were shown to be functionally normal in tests of their mobility and bactericidal activity. During the Phase II part of the patients were treated using a combination of i.v. Adriamycin, Ifosfamide and Etoposide. The chemotherapy was repeated every 3 weeks. rh G-CSF was given to each patient for 14 days on alternate cycles of chemotherapy and reduced the period of absolute neutropenia considerably (median of 80%), with a return to normal, or above normal, neutrophil counts within 2 weeks after day 1 of chemotherapy. Ten severe infective episodes were observed during the 20 cycles of chemotherapy which did not include rh G-CSF, while only one infective episode occurred in 20 courses when treated with rh G-CSF. These results demonstrate the utility of rh G-CSF in restoring functional neutrophils to patients undergoing intensive chemotherapy.Citation
Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. 1988 (83):327-9 Behring Inst. Mitt.Journal
Behring Institute MitteilungenPubMed ID
2467655Type
ArticleLanguage
enISSN
0301-0457Related articles
- [Effect of recombinant human granulocyte colony-stimulating factor (rG-CSF) on chemotherapy-induced neutropenia in patients with lung cancer].
- Authors: Ohnoshi T, Ueoka H, Kodani T, Kamei H, Kimura I
- Issue date: 1990 Apr
- Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer.
- Authors: Bronchud MH, Scarffe JH, Thatcher N, Crowther D, Souza LM, Alton NK, Testa NG, Dexter TM
- Issue date: 1987 Dec
- The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy.
- Authors: Crawford J, George M
- Issue date: 1995 Jun
- Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
- Authors: Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G
- Issue date: 1991 Jul 18
- Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
- Authors: Brugger W, Frommhold H, Pressler K, Mertelsmann R, Kanz L
- Issue date: 1995 Feb